HMGB1

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
Wednesday, November 29, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models

Retrieved on: 
Tuesday, April 18, 2023

The preclinical study, entitled “Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma,” showed highly potent anticancer activity of THIO in multiple HCC preclinical models.

Key Points: 
  • The preclinical study, entitled “Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma,” showed highly potent anticancer activity of THIO in multiple HCC preclinical models.
  • The study revealed the anti-tumor immune response role of THIO as a telomerase-dependent telomere targeting therapeutic in HCC models.
  • THIO induces telomere damage and activates the cGAS-STING pathway, which is a major intracellular signaling pathway that plays a role in innate immune responses.
  • THIO enhances the cross-priming capacity of dendritic cells (DCs), which are antigen presenting cells of the adaptive immune system and activates tumor specific T cells.

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Retrieved on: 
Monday, February 27, 2023

WESTON, Fla., Feb. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) reviewed Cantex's Investigational New Drug application and issued a "Study May Proceed" letter for Cantex's Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy. Azeliragon was recently granted FDA Orphan Drug Designation for the treatment of glioblastoma.

Key Points: 
  • Azeliragon was recently granted FDA Orphan Drug Designation for the treatment of glioblastoma.
  • "We are very pleased to have received this favorable response from the FDA enabling Cantex to initiate a Phase 2 clinical trial of azeliragon for the treatment of glioblastoma," commented Stephen G. Marcus, M.D., Chief Executive Officer of Cantex.
  • By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment.
  • Dr. Marcus continued: "The Phase 2 trial of azeliragon in glioblastoma is one of several promising clinical programs we continue to advance with azeliragon to treat cancer and other diseases where RAGE is implicated.

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Retrieved on: 
Monday, January 9, 2023

WESTON, Fla., Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.

Key Points: 
  • WESTON, Fla., Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.
  • By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment.
  • "Receiving FDA orphan drug status for azeliragon highlights the significant unmet need for novel treatment options for patients with glioblastoma, the most common and lethal primary brain cancer," commented Stephen G. Marcus, M.D., Chief Executive Officer of Cantex.
  • FDA Orphan Drug Designation provides Cantex with seven years of azeliragon marketing exclusivity from the time of product launch for the orphan indication, and several other important benefits, including assistance in the drug development process, tax credits for clinical costs, and exemptions from certain FDA fees.

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

Retrieved on: 
Thursday, December 29, 2022

Our priorities continue to be our clinical programs, repurposing anti-Tumor Necrosis Factor (TNF) drugs for treating Dupuytren’s disease, frozen shoulder and post-operative delirium.

Key Points: 
  • Our priorities continue to be our clinical programs, repurposing anti-Tumor Necrosis Factor (TNF) drugs for treating Dupuytren’s disease, frozen shoulder and post-operative delirium.
  • The Dupuytren’s contracture trial phase 2B trial, led by Prof Nanchahal, the results of which we have previously announced, exceeded our expectations.
  • After reviewing our program and data, Dr. Watson stated, “This is re-purposing of an approved medicine for a new indication.
  • However, we remain confident that we will be able to move our products ahead as we have described.

A novel azapeptide editing method provides potential for new drug development, Feinstein Institutes research shows

Retrieved on: 
Monday, November 28, 2022

Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir (Reyataz).

Key Points: 
  • Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir (Reyataz).
  • View the full release here: https://www.businesswire.com/news/home/20221128005470/en/
    Dr. Yousef Al-Abed is co-director of the Institute of Bioelectrionic Medicine at the Feinstein Institutes for Medical Research.
  • A technology that circumvents these problems inherent to native peptides will change the future landscape of drug discovery, said Dr. Al-Abed.
  • The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

High-frequency Electrical Stimulation Helps Reduce Inflammation, Pain in New Feinstein Institutes Study

Retrieved on: 
Wednesday, October 5, 2022

And while pain is an important defense mechanism to protect the body and promote healing, chronic pain can be debilitating.

Key Points: 
  • And while pain is an important defense mechanism to protect the body and promote healing, chronic pain can be debilitating.
  • The research, led by Feinstein Institutes Sangeeta Chavan, PhD , showed in preclinical mice models that HFES inhibits neuroinflammatory mediator release by sensory neurons, called nociceptors, to reduce pain.
  • For your body to feel pain, neurons release molecules that kickstart the bodys immune response causing inflammation and pain.
  • We now have a better understanding as to why high-frequency stimulation helps attenuate inflammation and associated pain.

Inflammation Protein Contributes to Anemia of Chronic Disease by Preventing Red Blood Cell Formation

Retrieved on: 
Tuesday, January 18, 2022

(Credit: Feinstein Institutes)

Key Points: 
  • (Credit: Feinstein Institutes)
    For those with ACD, inflammation prevents the body from using stored iron to make enough healthy red blood cells, leading to anemia.
  • Common hormone therapy to promote blood cell formation erythropoietin (EPO) treatment has been shown ineffective for those with ACD.
  • You need red blood cells to carry oxygen throughout the body; the inability to do so is known as anemia.
  • Patients with chronic inflammation often develop anemia, but the molecular understanding remains unclear, said Dr. Blanc, corresponding author of the study.

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

Retrieved on: 
Wednesday, December 15, 2021

There is currently no approved therapeutic for limiting damage and fibrosis in patients with liver disorders such as Non-Alcoholic Steatohepatitis (NASH).

Key Points: 
  • There is currently no approved therapeutic for limiting damage and fibrosis in patients with liver disorders such as Non-Alcoholic Steatohepatitis (NASH).
  • 180 Life Sciences, through a collaboration led by Professor Jagdeep Nanchahal at the University of Oxford, is pursuing a program to identify novel therapeutic targets.
  • Dr. James Woody, CEO of 180 Life Sciences, commented, Liver diseases represent a large unmet medical need.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.